Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 8
Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Key opinion leaders discuss the challenges associated with step therapy requirements after initially selecting a drug class, the patient factors considered when deciding to switch a patient with non-relapsing secondary progressive multiple sclerosis to a different therapy, and whether payers commonly employ step therapy between different drug classes.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
Now Viewing
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- Do you ever encounter challenges with step therapy requirements after initially selecting a drug class?
- What patient factors do you consider when deciding to switch a patient to a different therapy in patients diagnosed with non-relapsing secondary progressive multiple sclerosis?
- Are step therapies typically used for drugs within the same class, or do payers typically use step therapy between different classes of drugs?
Related Videos
Related Content
Exploring Metabolic Links to Cognitive Impairment in MS
November 8th 2024Article
The complex relationship between possibly impaired cognitive function in patients with multiple sclerosis (MS) and fasting blood sugar, fasting insulin, and insulin sensitivity levels is the focus of new work that advances understanding of intricate biological connections.
Read More
